Effect of Multifactorial Intervention on Diabetic Macular Edema
C linical trials (1, 2) have shown that intensive control of blood glucose and hypertension reduce development of clinically significant macular edema (CSME). Elevated HbA 1c (A1C) is a risk for persistent CSME (3) . Gross proteinuria is associated with a 95% increase in the incidence of macular edema (4) . However, the effect of control of systemic factors before focal laser photocoagulation is not known. We aimed to determine whether multifactorial intervention over 4 -6 weeks before focal laser photocoagulation would reduce macular thickness.
In a prospective nonrandomized pilot study, 14 consecutive patients (10 men and 4 women, aged 44 -65 years) with type 2 diabetes presenting with nonproliferative diabetic retinopathy and CSME underwent multifactorial interventions including single or multiple modifications in oral hypoglycemic agents (n ϭ 10), atorvastatin (n ϭ 11), antihypertensive drugs (n ϭ 12), and losartan (n ϭ 4) to control A1C, fasting and postprandial blood glucose, systolic and diastolic blood pressure, lipid profile, and 24-h urinary proteins. Detailed ocular examination at recruitment and 6 weeks after interventions included fundus fluorescein angiography and measurement of macular thickness using stratus optical coherence tomography done between 12:00 P.M. and 3:00 P.M. Quantitative data are shown as means Ϯ SD. Intergroup comparison was performed by unpaired t test.
At 6 weeks postintervention, we found a statistically significant decrease in mean A1C (8.3 to 7.62%, P Ͻ 0.01), LDL (125.14 to 99.5 mg/dl, P Ͻ 0.001), fasting blood glucose (142.07 to 117.5 mg %, P Ͻ 0.01), systolic blood pressure (141.43 to 126.43 mmHg, P Ͻ 0.002), and diastolic blood pressure (87.14 to 81.54 mmHg, P Ͻ 0.001). There was significant decrease in mean retinal thickness in both central 1 mm (244.20 Ϯ 64.30 to 220.30 Ϯ 59.68 m, P Ͻ 0.001) and 6 mm (282.87 Ϯ 51.09 to 261.65 Ϯ 40.08 m, P Ͻ 0.001) of the macula that resulted in a trend toward improvement in visual acuity (logarithm of minimal angle of resolution 0.53 Ϯ 0.29 to 0.52 Ϯ 0.27).
Decreasing macular edema on optical coherence tomography with multifactorial control before laser photocoagulation is encouraging in the management of CSME. Reducing macular thickness facilitates application of a low-energy laser beam. Previously, we found that atorvastatin 6 weeks before focal laser photocoagulation reduced subfoveal migration of lipids in patients with macular edema and dyslipidemia (5) . We propose larger studies to determine the role of optimizing systemic factors before laser in CSME. The ؊8503 G/A Polymorphism of the Adiponectin Receptor 1 Gene Is Associated With Insulin Sensitivity Dependent on Adiposity A diponectin has beneficial effects on insulin sensitivity. Unexpectedly, adiponectin knockout mice exhibit no or only mild insulin resistance. Nevertheless, under a high-fat/high-carbohydrate diet, severe insulin resistance was induced in those animals (1). Consistent with this, recent evidence (2) suggests that the relationship of adiponectin with insulin sensitivity is stronger with increasing adiposity. In addition, a haplotype in the adiponectin gene was associated with type 2 diabetes only in obese and morbidly obese subjects but not in lean subjects (3) .
Single nucleotide polymorphisms (SNPs) of the genes encoding adiponectin receptor (ADIPOR) 1 and 2 were associated with type 2 diabetes (4) or prediabetes phenotypes (5) in some but not in all (6) studies. We found that the Ϫ8503 G/A SNP of the ADIPOR1 gene was associated with insulin sensitivity (7) . In a very recent study (6) in rather lean subjects with a mean BMI of 21 kg/m 2 , no associations with insulin sensitivity were found. In our study (7), subjects were more obese (BMI 26 kg/m 2 ). This new information lead us to investigate whether the association of the Ϫ8503 G/A SNP of ADIPOR1 with insulin sensitivity is modulated by adiposity. If this was the case, then this may partly explain the inconsistent results regarding SNPs of ADIPOR1 and 2.
Recently reported data (7) from 502 nondiabetic Caucasians were analyzed. Insulin sensitivity was estimated from an oral glucose tolerance test and determined during a euglycemic-hyperinsulinemic clamp (n ϭ 299). Subjects were divided into two groups by the median percentage of body fat (PFAT). In the more obese group (n ϭ 250, PFAT 27-55%), carriers of the Ϫ8503 A allele had lower insulin sensitivity estimated from the oral glucose tolerance test using the formula proposed by Matsuda and DeFronzo (8) (G/G, G/A, and A/A: 14.4 Ϯ 0.8, 11.9 Ϯ 0.9, and 9.2 Ϯ 1.7 arbitrary units, respectively, P ϭ 0.003, ANOVA) and determined during the clamp (0.07 Ϯ 0.005, 0.06 Ϯ 0.005, and 0.04 Ϯ 0.01 mol ⅐ kg Ϫ1 ⅐ min Ϫ1 ⅐ pmol/l Ϫ1 , respectively, P ϭ 0.007) compared with homozygous carriers of the G allele, independent of age, sex, and PFAT. In contrast, in the lean group (n ϭ 252, PFAT 7-26%), no significant relationships were found (oral glucose tolerance test: 24.6 Ϯ 1.0, 27.2 Ϯ 1.1, and 23.0 Ϯ 2.4, respectively, P ϭ 0.60; clamp: 0.13 Ϯ 0.006, 0.13 Ϯ 0.007, and 0.12 Ϯ 0.016, respectively, P ϭ 0.84).
In summary, we show that the A allele of the Ϫ8503 G/A SNP of the ADIPOR1 gene is associated with less insulin sensitivity only in more obese but not in lean individuals. This finding may be important for further studies on the relationships of genetic variants of ADIPOR1 and possibly of ADIPOR2 with metabolism.
